|
Ubamatamab Clinical Trials
5 actively recruiting trials across 4 locations
No change since May 2026
Also known as: REGN4018
Pipeline
Phase 2: 3Phase 1/2: 2
Top Sponsors
- Regeneron Pharmaceuticals4
- M.D. Anderson Cancer Center1
Indications
- Cancer5
- Fallopian Tube Cancer2
- Primary Peritoneal Cancer2
- Endometrial Cancer2
- Ovarian Cancer2
Birmingham, Alabama2 trials
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
The University of Alabama at Birmingham
Phase 2
Goodyear, Arizona1 trial
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Cancer Treatment Centers of America, Phoenix
Phase 2
Duarte, California1 trial
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
City of Hope Comprehensive Cancer Center
Phase 1/2
Houston, Texas1 trial
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
MD Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.